Replies to post #262718 on Anavex Life Sciences Corp (AVXL)

[sokol]

No, Steady T is correct: See this:

Access Programs and Why We Need to Tell Physicians About New Medicines Available to Patients
When it comes to healthcare, Australians are fortunate.

We have a world-class health care system that includes an amazing government initiated and managed scheme to ensure that new drugs – perhaps already approved internationally -- can be made available in this country, with the approval and supervision of treating doctors.

This scheme is known as the Special Access Scheme (SAS) and was introduced by Australia’s Therapeutics Goods Administrations (TGA) “in recognition that there are circumstances where patients need access to therapeutic goods that are not on the ARTG”. (https://www.tga.gov.au/form/special-access-scheme).

https://www.stabiopharma.com/index.php?q=access-programs-and-why-we-need-to-tell-physicians-about-new-medicines-available-to-patients1.html

[Steady_T]

I just finished reading the AU TGA website on the subject and it looks to me like any qualified medical professional can apply for permission to prescribe 2-73 for patients.

It does appear that it is on a case by case basis. My guess is that it would become a rubber stamp process rather quickly.